Transcatheter Aortic Valve Therapies
- 9 Downloads
Since the introduction of transcatheter aortic valve implantation (TAVI) in 2002 by Cribier, the management of patients with severe aortic stenosis has undergone substantial transformation. TAVI has emerged as an effective treatment option in patients with severe aortic stenosis in large part due to a robust evidence base generated by a series of randomized controlled trials. It is now the preferred treatment modality in intermediate-, high-, and prohibitive surgical risk patients. Randomized trials of low surgical risk patients have completed enrollment and may significantly increase the candidacy of TAVI patients when the results become available in early 2019. Despite the significant improvement in technology, there are challenging issues that need to be optimized such as pacemaker rates, stroke, valve durability and thrombosis. This chapter provides an overview of the evidence base, current technology, guidelines and challenging issues related to TAVI.
KeywordsBalloon aortic valvuloplasty PARTNER 1A trial PARTNER 1B trial PARTNER 2A trial Transcatheter aortic valve implantation Transcatheter aortic valve therapies
- 8.Beohar N, Whisenant B, Kirtane AJ, et al. The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons score in the Placement of Aortic Transcatheter Valves trial. J Thorac Cardiovasc Surg. 2014;148:2830–7.e1.CrossRefGoogle Scholar
- 13.Todaro D, Barbanti M. Current TAVR devices technical characteristics and evidence to date for FDA- and CE Mark-approved valves 2017 [updated April 2017]. Available from: https://citoday.com/pdfs/cit0317_F5_Barbanti.pdf.
- 25.Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.CrossRefGoogle Scholar
- 35.Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2440–92.CrossRefGoogle Scholar
- 37.Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014;174:624–7.CrossRefGoogle Scholar
- 38.Rodes-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–65.CrossRefGoogle Scholar